FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221072014> ?p ?o ?g. }

• W4221072014 endingPage "e347" @default.
• W4221072014 startingPage "e336" @default.
• W4221072014 abstract "Tafenoquine was recently approved as a prophylaxis and radical cure for Plasmodium vivax infection, but its Plasmodium falciparum transmission-blocking efficacy is unclear. We aimed to establish the efficacy and safety of three single low doses of tafenoquine in combination with dihydroartemisinin-piperaquine for reducing gametocyte density and transmission to mosquitoes.In this four-arm, single-blind, phase 2, randomised controlled trial, participants were recruited at the Clinical Research Unit of the Malaria Research and Training Centre of the University of Bamako in Mali. Eligible participants were aged 12-50 years, with asymptomatic P falciparum microscopy-detected gametocyte carriage, had a bodyweight of 80 kg or less, and had no clinical signs of malaria defined by fever. Participants were randomly assigned (1:1:1:1) to standard treatment with dihydroartemisinin-piperaquine, or dihydroartemisinin-piperaquine plus a single dose of tafenoquine (in solution) at a final dosage of 0·42 mg/kg, 0·83 mg/kg, or 1·66 mg/kg. Randomisation was done with a computer-generated randomisation list and concealed with sealed, opaque envelopes. Dihydroartemisinin-piperaquine was administered as oral tablets over 3 days (day 0, 1, and 2), as per manufacturer instructions. A single dose of tafenoquine was administered as oral solution on day 0 in parallel with the first dose of dihydroartemisinin-piperaquine. Tafenoquine dosing was based on bodyweight to standardise efficacy and risk variance. The primary endpoint, assessed in the per-protocol population, was median percentage change in mosquito infection rate 7 days after treatment compared with baseline. Safety endpoints included frequency and incidence of adverse events. The final follow-up visit was on Dec 23, 2021; the trial is registered with ClinicalTrials.gov, NCT04609098.From Oct 29 to Nov 25, 2020, 1091 individuals were screened for eligibility, 80 of whom were enrolled and randomly assigned (20 per treatment group). Before treatment, 53 (66%) individuals were infectious to mosquitoes, infecting median 12·50% of mosquitoes (IQR 3·64-35·00). Within-group reduction in mosquito infection rate on day 7 was 79·95% (IQR 57·15-100; p=0·0005 for difference from baseline) following dihydroartemisinin-piperaquine only, 100% (98·36-100; p=0·0005) following dihydroartemisinin-piperaquine plus tafenoquine 0·42 mg/kg, 100% (100-100; p=0·0001) following dihydroartemisinin-piperaquine plus tafenoquine 0·83 mg/kg, and 100% (100-100; p=0·0001) following dihydroartemisinin-piperaquine plus tafenoquine 1·66 mg/kg. 55 (69%) of 80 participants had a total of 94 adverse events over the course of the trial; 86 (92%) adverse events were categorised as mild, seven (7%) as moderate, and one (1%) as severe. The most common treatment-related adverse event was mild or moderate headache, which occurred in 15 (19%) participants (dihydroartemisinin-piperaquine n=2; dihydroartemisinin-piperaquine plus tafenoquine 0·42 mg/kg n=6; dihydroartemisinin-piperaquine plus tafenoquine 0·83 mg/kg n=3; and dihydroartemisinin-piperaquine plus tafenoquine 1·66 mg/kg n=4). No serious adverse events occurred. No significant differences in the incidence of all adverse events (p=0·73) or treatment-related adverse events (p=0·62) were observed between treatment groups.Tafenoquine was well tolerated at all doses and accelerated P falciparum gametocyte clearance. All tafenoquine doses showed improved transmission reduction at day 7 compared with dihydroartemisinin-piperaquine alone. These data support the case for further research on tafenoquine as a transmission-blocking supplement to standard antimalarials.Bill & Melinda Gates Foundation.For the French, Portuguese, Spanish and Swahili translations of the abstract see Supplementary Materials section." @default.
• W4221072014 created "2022-04-03" @default.
• W4221072014 creator A5008023495 @default.
• W4221072014 creator A5012870282 @default.
• W4221072014 creator A5015531006 @default.
• W4221072014 creator A5015683419 @default.
• W4221072014 creator A5026462000 @default.
• W4221072014 creator A5027260115 @default.
• W4221072014 creator A5031546052 @default.
• W4221072014 creator A5036396443 @default.
• W4221072014 creator A5037076197 @default.
• W4221072014 creator A5037095663 @default.
• W4221072014 creator A5037712899 @default.
• W4221072014 creator A5053467206 @default.
• W4221072014 creator A5062591099 @default.
• W4221072014 creator A5065417937 @default.
• W4221072014 creator A5065803383 @default.
• W4221072014 creator A5068366279 @default.
• W4221072014 creator A5073162276 @default.
• W4221072014 creator A5075570673 @default.
• W4221072014 creator A5077345144 @default.
• W4221072014 creator A5080399165 @default.
• W4221072014 creator A5080694704 @default.
• W4221072014 creator A5088925800 @default.
• W4221072014 date "2022-05-01" @default.
• W4221072014 modified "2023-10-17" @default.
• W4221072014 title "Single low-dose tafenoquine combined with dihydroartemisinin–piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial" @default.
• W4221072014 cites W1505064888 @default.
• W4221072014 cites W2088888368 @default.
• W4221072014 cites W2104386816 @default.
• W4221072014 cites W2108523891 @default.
• W4221072014 cites W2130028379 @default.
• W4221072014 cites W2131174404 @default.
• W4221072014 cites W2134780685 @default.
• W4221072014 cites W2137269292 @default.
• W4221072014 cites W2149026206 @default.
• W4221072014 cites W2157838912 @default.
• W4221072014 cites W2158149195 @default.
• W4221072014 cites W2275939958 @default.
• W4221072014 cites W2278941756 @default.
• W4221072014 cites W2415685063 @default.
• W4221072014 cites W2427443000 @default.
• W4221072014 cites W2567209246 @default.
• W4221072014 cites W2592645342 @default.
• W4221072014 cites W2614319871 @default.
• W4221072014 cites W2739361295 @default.
• W4221072014 cites W2767584895 @default.
• W4221072014 cites W2785868810 @default.
• W4221072014 cites W2891642255 @default.
• W4221072014 cites W2892375818 @default.
• W4221072014 cites W2902369450 @default.
• W4221072014 cites W2912217112 @default.
• W4221072014 cites W3096542129 @default.
• W4221072014 cites W3205678266 @default.
• W4221072014 cites W4200105582 @default.
• W4221072014 doi "https://doi.org/10.1016/s2666-5247(21)00356-6" @default.
• W4221072014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35544095" @default.
• W4221072014 hasPublicationYear "2022" @default.
• W4221072014 type Work @default.
• W4221072014 citedByCount "9" @default.
• W4221072014 countsByYear W42210720142022 @default.
• W4221072014 countsByYear W42210720142023 @default.
• W4221072014 crossrefType "journal-article" @default.
• W4221072014 hasAuthorship W4221072014A5008023495 @default.
• W4221072014 hasAuthorship W4221072014A5012870282 @default.
• W4221072014 hasAuthorship W4221072014A5015531006 @default.
• W4221072014 hasAuthorship W4221072014A5015683419 @default.
• W4221072014 hasAuthorship W4221072014A5026462000 @default.
• W4221072014 hasAuthorship W4221072014A5027260115 @default.
• W4221072014 hasAuthorship W4221072014A5031546052 @default.
• W4221072014 hasAuthorship W4221072014A5036396443 @default.
• W4221072014 hasAuthorship W4221072014A5037076197 @default.
• W4221072014 hasAuthorship W4221072014A5037095663 @default.
• W4221072014 hasAuthorship W4221072014A5037712899 @default.
• W4221072014 hasAuthorship W4221072014A5053467206 @default.
• W4221072014 hasAuthorship W4221072014A5062591099 @default.
• W4221072014 hasAuthorship W4221072014A5065417937 @default.
• W4221072014 hasAuthorship W4221072014A5065803383 @default.
• W4221072014 hasAuthorship W4221072014A5068366279 @default.
• W4221072014 hasAuthorship W4221072014A5073162276 @default.
• W4221072014 hasAuthorship W4221072014A5075570673 @default.
• W4221072014 hasAuthorship W4221072014A5077345144 @default.
• W4221072014 hasAuthorship W4221072014A5080399165 @default.
• W4221072014 hasAuthorship W4221072014A5080694704 @default.
• W4221072014 hasAuthorship W4221072014A5088925800 @default.
• W4221072014 hasBestOaLocation W42210720141 @default.
• W4221072014 hasConcept C126322002 @default.
• W4221072014 hasConcept C203014093 @default.
• W4221072014 hasConcept C2776120307 @default.
• W4221072014 hasConcept C2777616469 @default.
• W4221072014 hasConcept C2778048844 @default.
• W4221072014 hasConcept C2778371730 @default.
• W4221072014 hasConcept C2781160685 @default.
• W4221072014 hasConcept C2908647359 @default.
• W4221072014 hasConcept C71924100 @default.
• W4221072014 hasConcept C99454951 @default.
• W4221072014 hasConceptScore W4221072014C126322002 @default.
• W4221072014 hasConceptScore W4221072014C203014093 @default.

• next